Q3 EPS Estimates for Gossamer Bio Boosted by HC Wainwright

Gossamer Bio, Inc. (NASDAQ:GOSS) – Equities researchers at HC Wainwright lifted their Q3 2026 earnings per share (EPS) estimates for shares of Gossamer Bio in a report issued on Thursday, March 19th. HC Wainwright analyst P. Trucchio now expects that the company will earn ($0.07) per share for the quarter, up from their prior forecast of ($0.08). HC Wainwright currently has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for Gossamer Bio’s current full-year earnings is ($0.28) per share. HC Wainwright also issued estimates for Gossamer Bio’s FY2026 earnings at ($0.20) EPS, Q1 2027 earnings at ($0.09) EPS, Q2 2027 earnings at ($0.09) EPS, Q3 2027 earnings at ($0.04) EPS, Q4 2027 earnings at ($0.01) EPS, FY2027 earnings at ($0.23) EPS, FY2028 earnings at ($0.16) EPS and FY2029 earnings at ($0.07) EPS.

Several other research firms have also issued reports on GOSS. Wedbush reissued a “neutral” rating and set a $1.00 price target (down from $6.00) on shares of Gossamer Bio in a research report on Tuesday, February 24th. The Goldman Sachs Group lowered shares of Gossamer Bio from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 24th. Leerink Partners cut shares of Gossamer Bio from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 24th. Royal Bank Of Canada raised shares of Gossamer Bio to an “outperform” rating in a report on Tuesday, February 24th. Finally, Oppenheimer dropped their price objective on shares of Gossamer Bio from $12.00 to $3.00 and set an “outperform” rating on the stock in a research note on Thursday, March 5th. Five research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $5.43.

Gossamer Bio Stock Performance

Shares of Gossamer Bio stock opened at $0.42 on Monday. The firm’s 50-day simple moving average is $1.65 and its 200-day simple moving average is $2.45. Gossamer Bio has a 1 year low of $0.33 and a 1 year high of $3.87. The firm has a market cap of $99.14 million, a PE ratio of -0.56 and a beta of 2.09.

Gossamer Bio (NASDAQ:GOSS) last issued its quarterly earnings results on Tuesday, March 17th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). Gossamer Bio had a negative return on equity of 1,774.72% and a negative net margin of 351.49%.The company had revenue of $13.80 million during the quarter, compared to the consensus estimate of $7.53 million.

Hedge Funds Weigh In On Gossamer Bio

Several institutional investors have recently modified their holdings of the company. Rockefeller Capital Management L.P. increased its holdings in shares of Gossamer Bio by 496.7% in the 4th quarter. Rockefeller Capital Management L.P. now owns 60,866 shares of the company’s stock worth $189,000 after acquiring an additional 50,666 shares during the period. Corient Private Wealth LLC lifted its position in Gossamer Bio by 19,123.7% in the 4th quarter. Corient Private Wealth LLC now owns 3,845,885 shares of the company’s stock valued at $11,922,000 after purchasing an additional 3,825,879 shares during the last quarter. Invesco Ltd. boosted its stake in Gossamer Bio by 36.0% during the 4th quarter. Invesco Ltd. now owns 478,909 shares of the company’s stock valued at $1,485,000 after purchasing an additional 126,823 shares during the period. Mercer Global Advisors Inc. ADV boosted its stake in Gossamer Bio by 52.3% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 23,983 shares of the company’s stock valued at $74,000 after purchasing an additional 8,239 shares during the period. Finally, Beacon Pointe Advisors LLC bought a new position in Gossamer Bio in the 4th quarter worth about $34,000. Institutional investors own 81.23% of the company’s stock.

Key Gossamer Bio News

Here are the key news stories impacting Gossamer Bio this week:

• Positive Sentiment: HC Wainwright reaffirmed a “Buy” rating and a $5.00 price target on GOSS, which provides a clear upside reference for investors relative to the current share price. HC Wainwright note (coverage)
• Positive Sentiment: The same HC Wainwright updates included upward revisions to some near‑term/near‑midterm estimates (notably FY2026 and FY2028 and a modest lift to Q3 2026 EPS), which suggests the analyst sees better operating/financial performance versus prior forecasts. HC Wainwright estimates update
• Neutral Sentiment: HC Wainwright’s changes are mixed overall — while some years were improved, FY2027 and FY2029 estimates were trimmed, leaving guidance directionally uncertain despite the maintained Buy rating. HC Wainwright mixed revisions
• Negative Sentiment: Levi & Korsinsky has opened a shareholder investigation alleging potential federal securities‑law violations related to Gossamer’s lead program (seralutinib) and the pivotal PROSERA Phase 3 trial — this raises legal and disclosure risk and typically weighs on the stock until details are resolved. Shareholders Alert: Investigation Into Gossamer Bio, Inc. (GOSS)

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.